905 related articles for article (PubMed ID: 33067320)
1. Impact of COVID-19 on patients with rheumatic complications of cancer immunotherapy: results of a registry survey.
Ghosh N; Tirpack A; Chan KK; Bass AR
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33067320
[TBL] [Abstract][Full Text] [Related]
2. Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists.
Ottaviano M; Curvietto M; Rescigno P; Tortora M; Palmieri G; Giannarelli D; Aieta M; Assalone P; Attademo L; Avallone A; Bloise F; Bosso D; Borzillo V; Buono G; Calderoni G; Caputo F; Cartenì G; Cavallero D; Cavo A; Ciardiello F; Conca R; Conteduca V; De Falco S; De Felice M; De Laurentiis M; De Placido P; De Placido S; De Santo I; De Stefano A; Della Corte CM; Di Franco R; Di Lauro V; Fabbrocini A; Federico P; Festino L; Giordano P; Giuliano M; Gridelli C; Grimaldi AM; Lia M; Marretta AL; Massa V; Mennitto A; Merler S; Merz V; Messina C; Messina M; Milano M; Minisini AM; Montesarchio V; Morabito A; Morgillo F; Mucci B; Nappi L; Napolitano F; Paciolla I; Pagliuca M; Palmieri G; Parola S; Pepe S; Petrillo A; Piantedosi F; Piccin L; Picozzi F; Pietroluongo E; Pignata S; Prati V; Riccio V; Rosanova M; Rossi A; Russo A; Salati M; Santabarbara G; Sbrana A; Simeone E; Silvestri A; Spada M; Tarantino P; Taveggia P; Tomei F; Vincenzo T; Trapani D; Trojanello C; Vanella V; Vari S; Ventriglia J; Vitale MG; Vitiello F; Vivaldi C; von Arx C; Zacchi F; Zampiva I; Zivi A; Daniele B; Ascierto PA;
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33060148
[TBL] [Abstract][Full Text] [Related]
3. Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era.
Maio M; Hamid O; Larkin J; Covre A; Altomonte M; Calabrò L; Vardhana SA; Robert C; Ibrahim R; Anichini A; Wolchok JD; Giacomo AMD
Clin Cancer Res; 2020 Aug; 26(16):4201-4205. PubMed ID: 32540850
[TBL] [Abstract][Full Text] [Related]
4. ICI Impact on COVID-19 Severity Modest at Best.
Cancer Discov; 2020 Oct; 10(10):1432-1433. PubMed ID: 32816844
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy is a preferred option for oral cancer patients during COVID-19 pandemic?
Chu C; Sun Y; Pan Y
Oral Oncol; 2020 Aug; 107():104860. PubMed ID: 32571643
[No Abstract] [Full Text] [Related]
6. Pneumonitis from immune checkpoint inhibitors and COVID-19: current concern in cancer treatment.
Rossi E; Schinzari G; Tortora G
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32699182
[TBL] [Abstract][Full Text] [Related]
7. Survey of the Impact of COVID-19 on Oncologists' Decision Making in Cancer.
Ürün Y; Hussain SA; Bakouny Z; Castellano D; Kılıçkap S; Morgan G; Mckay RR; Pels K; Schmidt A; Doroshow DB; Schütz F; Albiges L; Lopes G; Catto JWF; Peters S; Choueiri TK
JCO Glob Oncol; 2020 Aug; 6():1248-1257. PubMed ID: 32755479
[TBL] [Abstract][Full Text] [Related]
8. Case series of cancer patients who developed cholecystitis related to immune checkpoint inhibitor treatment.
Abu-Sbeih H; Tran CN; Ge PS; Bhutani MS; Alasadi M; Naing A; Jazaeri AA; Wang Y
J Immunother Cancer; 2019 May; 7(1):118. PubMed ID: 31053161
[TBL] [Abstract][Full Text] [Related]
9. Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinoma.
Aeppli S; Eboulet EI; Eisen T; Escudier B; Fischer S; Larkin J; Gruenwald V; McDermott D; Oldenburg J; Omlin A; Porta C; Rini B; Schmidinger M; Sternberg C; Rothermundt C
ESMO Open; 2020 Jul; 5(Suppl 3):. PubMed ID: 32669298
[TBL] [Abstract][Full Text] [Related]
10. Not all immune-checkpoint inhibitors are created equal: Meta-analysis and systematic review of immune-related adverse events in cancer trials.
El Osta B; Hu F; Sadek R; Chintalapally R; Tang SC
Crit Rev Oncol Hematol; 2017 Nov; 119():1-12. PubMed ID: 29065979
[TBL] [Abstract][Full Text] [Related]
11. Perspective of Oncology Patients During COVID-19 Pandemic: A Prospective Observational Study From India.
Ghosh J; Ganguly S; Mondal D; Pandey P; Dabkara D; Biswas B
JCO Glob Oncol; 2020 Jun; 6():844-851. PubMed ID: 32552110
[TBL] [Abstract][Full Text] [Related]
12. Immune checkpoint blockade: releasing the breaks or a protective barrier to COVID-19 severe acute respiratory syndrome?
Pickles OJ; Lee LYW; Starkey T; Freeman-Mills L; Olsson-Brown A; Cheng V; Hughes DJ; Lee A; Purshouse K; Middleton G
Br J Cancer; 2020 Sep; 123(5):691-693. PubMed ID: 32546835
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis.
Le Burel S; Champiat S; Mateus C; Marabelle A; Michot JM; Robert C; Belkhir R; Soria JC; Laghouati S; Voisin AL; Fain O; Mékinian A; Coutte L; Szwebel TA; Dunogeant L; Lioger B; Luxembourger C; Mariette X; Lambotte O
Eur J Cancer; 2017 Sep; 82():34-44. PubMed ID: 28646772
[TBL] [Abstract][Full Text] [Related]
14. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review.
Khoja L; Day D; Wei-Wu Chen T; Siu LL; Hansen AR
Ann Oncol; 2017 Oct; 28(10):2377-2385. PubMed ID: 28945858
[TBL] [Abstract][Full Text] [Related]
15. Checkpoint inhibitor pneumonitis mimicking COVID-19 infection during the COVID-19 pandemic.
Chang HL; Wei PJ; Wu KL; Huang HL; Yang CJ
Lung Cancer; 2020 Aug; 146():376-377. PubMed ID: 32576385
[No Abstract] [Full Text] [Related]
16. Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series.
Mitchell EL; Lau PKH; Khoo C; Liew D; Leung J; Liu B; Rischin A; Frauman AG; Kee D; Smith K; Brady B; Rischin D; Gibson A; Mileshkin L; Klein O; Weickhardt A; Arulananda S; Shackleton M; McArthur G; Östör A; Cebon J; Solomon B; Buchanan RR; Wicks IP; Lo S; Hicks RJ; Sandhu S
Eur J Cancer; 2018 Dec; 105():88-102. PubMed ID: 30439628
[TBL] [Abstract][Full Text] [Related]
17. Prevalence and Clinical Patterns of Ocular Complications Associated With Anti-PD-1/PD-L1 Anticancer Immunotherapy.
Bitton K; Michot JM; Barreau E; Lambotte O; Haigh O; Marabelle A; Voisin AL; Mateus C; Rémond AL; Couret C; Champiat S; Labetoulle M; Rousseau A
Am J Ophthalmol; 2019 Jun; 202():109-117. PubMed ID: 30772350
[TBL] [Abstract][Full Text] [Related]
18. Immune-related (IR)-pneumonitis during the COVID-19 pandemic: multidisciplinary recommendations for diagnosis and management.
Naidoo J; Reuss JE; Suresh K; Feller-Kopman D; Forde PM; Mehta Steinke S; Rock C; Johnson DB; Nishino M; Brahmer JR
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32554619
[TBL] [Abstract][Full Text] [Related]
19. Association of good oncological response to therapy with the development of rheumatic immune-related adverse events following PD-1 inhibitor therapy.
Liew DFL; Leung JLY; Liu B; Cebon J; Frauman AG; Buchanan RRC
Int J Rheum Dis; 2019 Feb; 22(2):297-302. PubMed ID: 30549256
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma.
Abou Alaiwi S; Xie W; Nassar AH; Dudani S; Martini D; Bakouny Z; Steinharter JA; Nuzzo PV; Flippot R; Martinez-Chanza N; Wei X; McGregor BA; Kaymakcalan MD; Heng DYC; Bilen MA; Choueiri TK; Harshman LC
J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32066646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
